📊 CUE Key Takeaways
Investment Thesis
Cue Biopharma exhibits severe financial distress with massive operating losses (-96.7% margin) despite 7,793% revenue growth, indicating unsustainable burn rate and pre-commercial stage losses. The company is burning cash at an alarming rate (-$21.7M operating cash flow on $27.5M revenue) and will exhaust its $27.1M cash reserve within 14 months at current burn, leaving minimal runway for clinical development.
CUE Strengths
- Strong liquidity position with $27.1M cash and 2.74x current ratio providing near-term operational flexibility
- Dramatic 7,793% revenue growth suggests early commercialization or partnerships beginning to generate income
- Zero long-term debt reduces financial leverage risk and future solvency concerns
CUE Risks
- Severe cash burn of -$21.9M free cash flow with only 14 months of runway at current burn rate before insolvency
- Operating margin of -96.7% and net margin of -96.9% indicate fundamental unprofitability and no path to profitability visible
- Negative ROE (-100.6%) and ROA (-63.0%) demonstrate value destruction and inefficient capital deployment
- Operating cash outflows of -$21.7M on $27.5M revenue indicates business model not yet sustainable
Key Metrics to Watch
- Monthly cash burn rate and cash runway remaining
- Path to operating profitability and timeline to breakeven
- Revenue growth sustainability and gross margin realization
CUE Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.74x current ratio provides a solid financial cushion.
CUE Profitability Ratios
CUE vs Healthcare Sector
How Cue Biopharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CUE Balance Sheet & Liquidity
CUE 5-Year Financial Trend
5-Year Trend Summary: Cue Biopharma, Inc.'s revenue has grown significantly by 84% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.72 indicates the company is currently unprofitable.
CUE Growth Metrics (YoY)
CUE Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.1M | -$7.4M | $-0.07 |
| Q2 2025 | $2.7M | -$8.5M | $-0.09 |
| Q1 2025 | $421.0K | -$12.3M | $-0.17 |
| Q3 2024 | $2.1M | -$8.7M | $-0.17 |
| Q2 2024 | $1.4M | -$10.2M | $-0.20 |
| Q1 2024 | $187.0K | -$12.3M | $-0.25 |
| Q3 2023 | $68.0K | -$11.0M | $-0.24 |
| Q2 2023 | $26.0K | -$13.2M | $-0.29 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CUE Capital Allocation
CUE SEC Filings
Access official SEC EDGAR filings for Cue Biopharma, Inc. (CIK: 0001645460)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CUE
What is the AI rating for CUE?
Cue Biopharma, Inc. (CUE) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CUE's key strengths?
Strong liquidity position with $27.1M cash and 2.74x current ratio providing near-term operational flexibility. Dramatic 7,793% revenue growth suggests early commercialization or partnerships beginning to generate income.
What are the risks of investing in CUE?
Severe cash burn of -$21.9M free cash flow with only 14 months of runway at current burn rate before insolvency. Operating margin of -96.7% and net margin of -96.9% indicate fundamental unprofitability and no path to profitability visible.
What is CUE's revenue and growth?
Cue Biopharma, Inc. reported revenue of $27.5M.
Does CUE pay dividends?
Cue Biopharma, Inc. does not currently pay dividends.
Where can I find CUE SEC filings?
Official SEC filings for Cue Biopharma, Inc. (CIK: 0001645460) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CUE's EPS?
Cue Biopharma, Inc. has a diluted EPS of $-0.28.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.